|
|
|
Insider
Information: |
Vaishnaw Akshay |
Relationship: |
President |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
22,774 |
|
Indirect Shares
|
515 |
|
|
Direct
Value |
$3,380,345 |
|
|
Indirect Value
|
$76,441 |
|
|
Total
Shares |
23,289 |
|
|
Total
Value |
$3,456,786 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
2
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
Percentage
Gain/Loss : |
0.0%
|
-26.9%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alnylam Pharmaceuticals Inc |
ALNY |
President |
2023-08-04 |
22,774 |
2023-08-04 |
515 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
96 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALNY |
Alnylam Pharmaceuticals I... |
SVP, Clinical ResearchOfficer |
|
2009-03-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
799 |
|
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
|
2017-12-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
320 |
11,215 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
28 |
366 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
I/I |
29 |
395 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2018-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,724 |
12,939 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2018-10-18 |
4 |
A |
$0.00 |
$0 |
I/I |
21 |
416 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2019-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
51 |
467 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2019-07-11 |
4 |
A |
$0.00 |
$0 |
I/I |
48 |
515 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
16,632 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2021-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,416 |
19,535 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2021-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,083 |
22,908 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2021-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,417 |
16,632 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President |
|
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,183 |
24,398 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President |
|
2023-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,312 |
20,282 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President |
|
2023-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
8,941 |
26,831 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
|
2012-09-10 |
4 |
OE |
$9.30 |
$12,406 |
D/D |
1,334 |
13,922 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
|
2012-12-04 |
4 |
OE |
$7.10 |
$17,040 |
D/D |
2,400 |
14,988 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
|
2012-11-30 |
4 |
OE |
$7.10 |
$20,043 |
D/D |
2,823 |
15,411 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
|
2012-09-10 |
4 |
AS |
$19.00 |
$25,346 |
D/D |
(1,334) |
12,588 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
|
2017-06-13 |
4 |
D |
$74.31 |
$31,953 |
D/D |
(430) |
11,535 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, R&D |
|
2017-06-13 |
4 |
OE |
$18.66 |
$32,007 |
D/D |
1,668 |
11,965 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
|
2012-12-10 |
4 |
OE |
$7.10 |
$33,917 |
D/D |
4,777 |
17,365 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
EVP, Chief Medical Officer |
|
2012-12-04 |
4 |
AS |
$17.04 |
$40,896 |
D/D |
(2,400) |
12,588 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2020-06-22 |
4 |
OE |
$42.22 |
$40,953 |
D/D |
970 |
15,089 |
0 |
- |
|
ALNY |
Alnylam Pharmaceuticals I... |
President, R&D |
|
2020-09-29 |
4 |
OE |
$42.22 |
$40,996 |
D/D |
971 |
15,090 |
0 |
- |
|
96 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|